Table 3.
Relative Difference (%) in Mean Sprint Power | |||
---|---|---|---|
Low HMS–G | Iso HMS–G | Iso HMS–Low HMS | |
Unadjusted mean sprint power | −5.0; ±5.3 | −0.6; ±3.0 | 4.4; ±3.2 |
likely small | likely trivial | likely small | |
Effect of gastrointestinal distress | −5.5; ±2.2 | −1.4; ±1.4 | −0.3; ±0.2 |
very likely small ** | unclear | Unclear ** | |
Effect independent of gastrointestinal distress | 0.4; ±3.5 | 0.8; ±3.1 | 4.7; ±2.7 |
Unclear ** | likely trivial | likely small | |
Effect of Individual Symptoms | |||
Effect of nausea | −5.2; ±2.7 | −1.4; ±1.6 | 0.1; ±0.1 |
Unclear ** | likely trivial ** | Unclear ** | |
Effect independent of nausea | 0.1; ±4.2 | 0.9; ±3.2 | 4.4; ±2.7 |
Unclear ** | likely trivial ** | likely small | |
Effect of abdominal cramp | −2.9; ±2.0 ** | −0.3; ±0.6 | 0.4; ±1.4 |
unclear | most likely trivial ** | Unclear ** | |
Effect independent of abdominal cramp | −2.0; ±4.4 ** | −0.2; ±3.1 | 4.0; ±3.7 |
possibly trivial | Unclear ** | possibly small ** |
Note: Data is presented as relative differences between treatments ±90% confidence interval. G, a glucose and sucrose-based supplement; Low HMS, low dose of hydrothermally-modified starch; Iso HMS, an isocaloric dose (relative to G) of hydrothermally-modified starch; * gastrointestinal distress refers only to effects of nausea and abdominal cramp because ratings of fullness did not correlate with changes in performance; ** indicates a change in effect magnitude and/or inference mediated by the covariate.